Expression of pituitary adenylate cyclase-activating polypeptide (PACAP) receptors and PACAP in human fetal retina.
Specific receptors for pituitary adenylate cyclase-activating polypeptide (PACAP), a novel peptide with neuroregulatory and neurotrophic functions, have recently been identified in the retinas of different mammalian species. In the present study, expression of PACAP receptors and PACAP was investigated in the retinas of 12-18-week human embryos. Radioligand binding studies showed that the two forms of PACAP with 38 and 27 amino acids (PACAP 38 and PACAP 27, respectively) displaced the binding of 125I-PACAP 27 with IC50 values in the picomolar range, whereas functional receptor assays demonstrated that the two peptides were potent and effective stimulators of adenylyl cyclase activity. In contrast, vasoactive intestinal peptide (VIP) and human peptide histidine-isoleucine, which are homologous to PACAP, displayed lower affinities for the 125I-PACAP 27 binding site and were much less potent stimulators of cyclic AMP formation. Glucagon and secretin were inactive in both receptor assays. The expression of specific PACAP receptors was further investigated by reverse transcription-polymerase chain reaction technique, which showed the presence of mRNAs coding for PACAP type I and for nonselective PACAP type II (both VIP1 and VIP2) receptors. By the same technique, expression of PACAP mRNA was also detected. These data indicate that the developing human retina synthesizes PACAP and that the peptide may act on retinal cells by predominantly stimulating PACAP type I receptors coupled to cyclic AMP formation.
Olianas
M C
MC
Department of Neurosciences, University of Cagliari, Italy.
Ingianni
A
A
Sogos
V
V
Onali
P
P
D000028:Abortion, Induced; D001665:Binding Sites; D001667:Binding, Competitive; D017931:DNA Primers; D005260:Female; D005333:Fetus; D018507:Gene Expression Regulation, Developmental; D005934:Glucagon / Q000494:pharmacology; D006801:Humans; D009479:Neuropeptides / Q000096:biosynthesis* / Q000378:metabolism / Q000494:pharmacology; D018377:Neurotransmitter Agents / Q000096:biosynthesis; D010451:Peptide PHI / Q000494:pharmacology; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide; D016133:Polymerase Chain Reaction; D011247:Pregnancy; D011869:Radioligand Assay; D051236:Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide; D051237:Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I; D011979:Receptors, Pituitary Hormone / Q000096:biosynthesis*; D051238:Receptors, Vasoactive Intestinal Polypeptide, Type I; D012160:Retina / Q000196:embryology* / Q000378:metabolism*; D012633:Secretin / Q000494:pharmacology; D014660:Vasoactive Intestinal Peptide / Q000494:pharmacology
C495401:ADCYAP1 protein, human; D017931:DNA Primers; D009479:Neuropeptides; D018377:Neurotransmitter Agents; D010451:Peptide PHI; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide; D051236:Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide; D051237:Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I; D011979:Receptors, Pituitary Hormone; D051238:Receptors, Vasoactive Intestinal Polypeptide, Type I; C495506:VIPR1 protein, human; D012633:Secretin; D014660:Vasoactive Intestinal Peptide; D005934:Glucagon